Summarized by Masters of Longevity from Longevity Technology.
A news article about a newly FDA-cleared blood diagnostic for early Alzheimer’s, explaining its clinical role and potential impact. It previews what clinicians and patients might learn about using the test in routine cognitive evaluations.
Key Takeaways
- The FDA cleared a blood test that aids identification of brain amyloid pathology in symptomatic adults aged 40 and older.
- In a 1,142-person validation, the test showed 97.6% positive predictive value and 93.1% negative predictive value versus PET or CSF.
- The assay maintained consistent accuracy across 12 common chronic conditions including diabetes and chronic kidney disease.
